To view enhanced content for this article go to http://www.medengine.com/Redeem/D257F060381D5215.
Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs. SoC in a real-world, outpatient setting.
A single-site, retrospective chart review was conducted of 118 adult patients diagnosed with ABSSSI and treated with either single-dose oritavancin or multi-dose SoC therapy between 6 August 2014 and 30 June 2015. Patients were assigned to two matched cohorts: oritavancin and SoC. Primary clinical effectiveness endpoints was the success (cured or improved) at 5–30 days after the course of antibiotic therapy has been completed. Secondary economic endpoints were total costs and healthcare resource utilization.
Oritavancin showed comparable clinical effectiveness vs. multi-dose SoC in the outpatient setting. A similar percentage of patients in the oritavancin (90.2%) and SoC cohorts (77.4%) achieved successful outcomes (“cure” or “improved”), with the cure rate higher for oritavancin (73.2%) vs. SoC (48.4%; P = 0.0315). Oritavancin’s clinical effectiveness was consistent across patient subgroups with varying demographic, clinical, and ABSSSI characteristics. Oritavancin was consistently associated with lower costs (per-patient savings $2319) and reduced resource utilization measures, and it required just 1.0 day of therapy vs. 7.2 days for SoC.
Oritavancin is well suited for the outpatient treatment of ABSSSI. Compared with SoC, oritavancin offers comparable effectiveness, is more economical, and requires fewer healthcare resources.
Centers for Disease Control and Prevention (CDC). FastStats—Health Expenditures. http://www.cdc.gov/nchs/fastats/health-expenditures.htm. Accessed 30 July 2016.
HCUPnet. Healthcare Cost and Utilization Project (HCUP). Rockville: Agency for Healthcare Research and Quality. http://hcupnet.ahrq.gov/. Accessed 30 July 2016.
Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract. 2015;43(3):137–43. CrossRef
Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists. J Antimicrob Chemother. 2015;70(4):965–70. PubMed
Premier, Inc. Premier Research Services. Charlotte; 2016. https://www.premierinc.com/transforming-healthcare/healthcare-performance-improvement/premier-research-services/. Accessed Dec 12, 2016.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. 2013. http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf. Accessed 30 July 2016.
- Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
Patrick J. Anastasio
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II